NY-MORROW-SODALI
26.4.2022 15:02:06 CEST | Business Wire | Press release
Morrow Sodali, the leading global shareholder engagement and governance advisory firm, announced today that TPG Growth, the middle market and growth equity platform of alternative asset firm TPG, has acquired a majority stake in the company. The partnership with TPG will significantly advance Morrow Sodali’s mission of providing clients worldwide with unrivaled strategic advice and comprehensive support, enabling them to maximize value and expertly manage stakeholder relations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005374/en/
TPG’s investment coincides with Morrow Sodali’s 50th anniversary, which the company is celebrating with a series of special initiatives centered on the theme of “Building Together”. Throughout the year, Morrow Sodali will highlight the Company’s best-in-class expertise on emerging global trends in shareholder engagement matters impacting corporations, including ESG reporting, sustainability, climate change, board composition and evaluation, succession planning, executive compensation, shareholder activism and investor engagement.
Alvise Recchi, Chief Executive Officer of Morrow Sodali, said: "We are thrilled to become a TPG portfolio company. Joining forces with an organization of TPG's strength and breadth will allow us to further enhance our market leadership position, forged over decades of guiding clients through every critical trend impacting corporations, shareholders, and the financial markets. Our focus is on delivering value creation and as we move forward with TPG’s backing, we’ll grow that value for our clients, especially as they increase their focus on corporate purpose and the goals of diversity, inclusiveness, and sustainability.”
Ransom Langford, Partner at TPG, added: "Morrow Sodali’s differentiated ability to deliver results for its diverse set of clients, combined with a commitment to its values of integrity, excellence, collaboration, innovation and respect creates a unique opportunity for our partnership. As the focus on ESG continues to increase amongst companies and investors alike, Morrow Sodali has established itself as a trusted partner and global leader in proactive and trusted shareholder engagement. We look forward to working with the Morrow Sodali team to continue investing in the business’ extensive breadth of services and capabilities across the shareholder lifecycle."
Morrow Sodali recently secured the #1 position in 2021 M&A league tables released by both Mergermarket and The Deal. Morrow Sodali has made several highly strategic, global acquisitions and personnel investments, and, with the support of TPG, expects to accelerate those efforts.
ABOUT MORROW SODALI
Morrow Sodali is a global corporate advisory firm focused on shareholder engagement. The Company provides clients with comprehensive services relating to corporate governance , diversity equity & inclusion, sustainability, proxy solicitation , capital markets intelligence , shareholder and bondholder engagement, M&A , shareholder activism and contested situations .
Headquartered in New York and with offices in London, Sydney, Buenos Aires, Frankfurt, Hong Kong, Madrid, Melbourne, Paris, Rome, Sao Paolo, Seoul, Stamford, Toyko and Toronto, Morrow Sodali serves more than 850 clients in 80+ countries, including many of the world’s largest multinational corporations. Clients include publicly-listed and private companies, mutual fund groups, stock exchanges and membership associations. For more information about Morrow Sodali, please visit www.morrowsodali.com .
ABOUT TPG GROWTH
TPG Growth is the middle market and growth equity investment platform of TPG, the global alternative asset firm. With approximately $14.7 billion of assets under management, TPG Growth targets investments in a broad range of industries and geographies. TPG Growth has the deep sector knowledge, operational resources, and global experience to drive value creation, and help companies reach their full potential. The platform is backed by the resources of TPG, which has approximately $114 billion of assets under management. For more information, please visit www.tpg.com or on Twitter @TPG.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005374/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom